CY1120854T1 - Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι - Google Patents

Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι

Info

Publication number
CY1120854T1
CY1120854T1 CY181100923T CY181100923T CY1120854T1 CY 1120854 T1 CY1120854 T1 CY 1120854T1 CY 181100923 T CY181100923 T CY 181100923T CY 181100923 T CY181100923 T CY 181100923T CY 1120854 T1 CY1120854 T1 CY 1120854T1
Authority
CY
Cyprus
Prior art keywords
related methods
lipopeptide compositions
daptomycin
compositions
lipopeptide
Prior art date
Application number
CY181100923T
Other languages
English (en)
Inventor
Sophie Sun
Gaauri Naik
Sandra O’Connor
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120854(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Publication of CY1120854T1 publication Critical patent/CY1120854T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει νέες φαρμακοτεχνικές μορφές σκόνης δαπτομυκίνης, οι οποίες έχουν βελτιωμένη χημική σταθερότητα και ταχύτερους χρόνους επανασύστασης όταν βρίσκονται σε στερεά κατάσταση. Ορισμένα παραδείγματα των συνθέσεων περιλαμβάνουν δαπτομυκίνη και σακχαρόζη.
CY181100923T 2009-11-23 2018-09-04 Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι CY1120854T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Publications (1)

Publication Number Publication Date
CY1120854T1 true CY1120854T1 (el) 2019-12-11

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100923T CY1120854T1 (el) 2009-11-23 2018-09-04 Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι

Country Status (33)

Country Link
US (3) US8835382B2 (el)
EP (2) EP2504353B2 (el)
JP (3) JP6041673B2 (el)
CN (3) CN108785654A (el)
AR (2) AR079127A1 (el)
AU (1) AU2010321531C1 (el)
BR (1) BR112012012406B1 (el)
CA (1) CA2781666C (el)
CL (2) CL2012001336A1 (el)
CO (1) CO6541585A2 (el)
CR (1) CR20120271A (el)
CY (1) CY1120854T1 (el)
DK (1) DK2504353T4 (el)
DO (1) DOP2012000140A (el)
EC (1) ECSP12011939A (el)
ES (1) ES2686331T5 (el)
FI (1) FI2504353T4 (el)
HR (1) HRP20181380T4 (el)
HU (1) HUE039967T2 (el)
IL (1) IL219891B (el)
LT (1) LT2504353T (el)
MX (1) MX2012005993A (el)
NZ (1) NZ600118A (el)
PE (2) PE20121517A1 (el)
PL (1) PL2504353T5 (el)
PT (1) PT2504353T (el)
RS (1) RS57566B2 (el)
RU (1) RU2607526C2 (el)
SG (1) SG10201407724YA (el)
SI (1) SI2504353T2 (el)
TR (1) TR201812823T4 (el)
TW (2) TWI606838B (el)
WO (1) WO2011063419A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US8835382B2 (en) 2009-11-23 2014-09-16 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
BR112013030369A2 (pt) * 2011-05-26 2016-12-13 Cubist Pharm Inc composições de cb-183,315 e métodos relacionados
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
PT2887953T (pt) * 2012-08-23 2018-01-10 Mylan Laboratories Ltd Formulação injetável de daptomicina melhorada
EP4066849A1 (en) 2012-09-11 2022-10-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN111093625A (zh) * 2017-08-31 2020-05-01 埃克斯利亚制药有限公司 达托霉素制剂
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
KR102218688B1 (ko) * 2020-06-25 2021-02-22 주식회사 클린텍 무선제어기능을 구비한 고압세척기
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
EG17619A (en) 1984-10-09 1991-03-30 Lilly Co Eli An improved process for the production of a-21978 c derivatives
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
NZ232763A (en) 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
DE69031730T2 (de) 1990-01-26 1998-04-23 Hoechst Ag Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (el) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
ATE167871T1 (de) 1992-04-20 1998-07-15 Abbott Lab Verfahren zur herstellung von vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
BR9914051A (pt) 1998-09-25 2001-06-19 Cubist Pharm Inc Métodos para administração de antibióticos
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7408025B2 (en) 1999-12-15 2008-08-05 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
AU6701101A (en) * 2000-06-21 2002-01-02 Cubist Pharm Inc Compositions and methods to improve the oral absorption of antimicrobial agents
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重t細胞エピトープポリペプチドの酢酸塩組成物
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
WO2003059964A2 (fr) 2002-01-17 2003-07-24 Atofina Polymeres supramoleculaires
AU2003265264A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−11含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
US7960337B2 (en) * 2005-02-14 2011-06-14 Venues Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
WO2006130629A2 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
SI2049142T2 (sl) * 2006-07-26 2016-04-29 Sandoz Ag Formulacije kaspofungina
EP2084519B1 (en) 2006-10-10 2012-08-01 Los Alamos National Security, LLC X-ray fluorescence analysis method
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
JP2010530846A (ja) * 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
JP5350388B2 (ja) * 2007-10-25 2013-11-27 ノバルティス アーゲー 単位用量薬物パッケージの粉体調整
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2774094A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US8835382B2 (en) 2009-11-23 2014-09-16 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
WO2012061360A2 (en) 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions
AU2011348085B2 (en) 2010-12-23 2016-12-08 Alkermes Pharma Ireland Limited Multi- API loading prodrugs
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof

Also Published As

Publication number Publication date
SI2504353T1 (sl) 2018-10-30
PL2504353T5 (pl) 2023-11-20
JP2013511557A (ja) 2013-04-04
AR079127A1 (es) 2011-12-28
SG10201407724YA (en) 2014-12-30
CN102712677A (zh) 2012-10-03
EP2504353B2 (en) 2023-09-13
RS57566B2 (sr) 2023-12-29
IL219891A0 (en) 2012-07-31
CA2781666C (en) 2017-02-21
PL2504353T3 (pl) 2018-11-30
PT2504353T (pt) 2018-10-18
AR123846A2 (es) 2023-01-18
BR112012012406A2 (pt) 2019-12-03
TWI548414B (zh) 2016-09-11
JP2016147874A (ja) 2016-08-18
TW201703791A (zh) 2017-02-01
TR201812823T4 (tr) 2019-02-21
BR112012012406B1 (pt) 2021-11-16
WO2011063419A2 (en) 2011-05-26
AU2010321531B2 (en) 2016-11-03
CL2015002412A1 (es) 2016-02-05
MX2012005993A (es) 2012-11-23
EP3417849A1 (en) 2018-12-26
CL2012001336A1 (es) 2012-10-05
US20140364380A1 (en) 2014-12-11
IL219891B (en) 2018-01-31
CO6541585A2 (es) 2012-10-16
DK2504353T3 (en) 2018-09-10
LT2504353T (lt) 2018-09-25
EP2504353B1 (en) 2018-07-11
AU2010321531A2 (en) 2014-10-30
FI2504353T4 (fi) 2023-11-30
JP6088681B2 (ja) 2017-03-01
PE20121517A1 (es) 2012-11-26
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
US8835382B2 (en) 2014-09-16
ES2686331T3 (es) 2018-10-17
AU2010321531A1 (en) 2012-06-14
HUE039967T2 (hu) 2019-02-28
JP6239167B2 (ja) 2017-11-29
DOP2012000140A (es) 2012-10-30
US20120270772A1 (en) 2012-10-25
SI2504353T2 (sl) 2023-11-30
JP6041673B2 (ja) 2016-12-14
RS57566B1 (sr) 2018-10-31
US9138456B2 (en) 2015-09-22
EP2504353A2 (en) 2012-10-03
PE20151717A1 (es) 2015-11-19
RU2607526C2 (ru) 2017-01-10
CN102712677B (zh) 2015-06-03
CR20120271A (es) 2012-08-01
RU2012126076A (ru) 2013-12-27
NZ600118A (en) 2014-08-29
EP2504353A4 (en) 2014-04-02
JP2017075186A (ja) 2017-04-20
CN108785654A (zh) 2018-11-13
AU2010321531C1 (en) 2020-10-01
ECSP12011939A (es) 2012-07-31
WO2011063419A3 (en) 2011-10-13
US20160030577A1 (en) 2016-02-04
CA2781666A1 (en) 2011-05-26
DK2504353T4 (da) 2023-11-20
ES2686331T5 (es) 2024-03-27
HRP20181380T1 (hr) 2018-10-19
HRP20181380T4 (hr) 2023-11-10
CN104056250A (zh) 2014-09-24
US9662397B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CY1120854T1 (el) Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι
CY1119276T1 (el) Πολυπεπτιδια χλωροτοξινης και συζευγματα και χρησεις αυτων
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1119979T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile
CY1123217T1 (el) Παγιδες gdf
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
CY1124924T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CY1120638T1 (el) Αναστολεις τυροσινικης κινασης πυριμιδινυλιου
EA202090868A1 (ru) Составы
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
CY1118680T1 (el) Φαρμακευτικη συνθεση
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
EA201791383A1 (ru) Наноносители, имеющие компоненты с различными скоростями высвобождения
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
ECSP13012784A (es) Anticuerpos anti-mesotelina e inmunoconjugados
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CY1113713T1 (el) Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MX346950B (es) Reovirus que tienen secuencias modificadas.
EA201100268A1 (ru) Вакцина
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης